Literature DB >> 20413435

Modeling survival of arteriovenous accesses for hemodialysis: semiparametric versus parametric methods.

Pietro Ravani1, Patrick Parfrey, Jennifer MacRae, Matthew James, Robert Quinn, Fabio Malberti, Giuliano Brunori, Salvatore Mandolfo, Marcello Tonelli, Brenda Hemmelgarn, Braden Manns, Brendan Barrett.   

Abstract

BACKGROUND AND OBJECTIVES: Comparing outcomes of arteriovenous grafts and fistulas is challenging because the pathophysiology of access dysfunction and failure rate profiles differ by access type. Studying how risks vary over time may be important. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Longitudinal data from 535 incident hemodialysis patients were used to study the relationship between access type and access survival, without (semiparametric Cox modeling) and with specification of the underlying hazard function (parametric Weibull modeling).
RESULTS: The hazard for failure of fistulas and grafts declined over time, becoming proportional only after 3 months from surgery, with a graft versus fistula hazard ratio of 3.2 (95% confidence interval 1.9 to 5.3; Cox and Weibull estimation) and time ratio of 0.11 (i.e., the estimated access survival time was approximately one tenth shorter in grafts; 95% confidence interval 0.04 to 0.28; Weibull estimation only). Considering the entire observation period, grafts had slower hazard decline (P<0.001) with shorter median survival times than fistulas (8.4 versus 38.3 months; Weibull regression only).
CONCLUSIONS: Parametric models of arteriovenous access survival may provide relevant information about temporal risk profiles and predicted survival times.

Entities:  

Mesh:

Year:  2010        PMID: 20413435      PMCID: PMC2893071          DOI: 10.2215/CJN.06190809

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  10 in total

1.  Vascular access surgery managed by renal physicians: the choice of native arteriovenous fistulas for hemodialysis.

Authors:  Pietro Ravani; Daniele Marcelli; Fabio Malberti
Journal:  Am J Kidney Dis       Date:  2002-12       Impact factor: 8.860

Review 2.  Clinical research of kidney diseases V: extended analytic models.

Authors:  Pietro Ravani; Patrick Parfrey; Veeresh Gadag; Fabio Malberti; Brendan Barrett
Journal:  Nephrol Dial Transplant       Date:  2008-05       Impact factor: 5.992

3.  Factors associated with unsuccessful utilization and early failure of the arterio-venous fistula for hemodialysis.

Authors:  Pietro Ravani; Brendan Barrett; Salvatore Mandolfo; Giuliano Brunori; Giovanni Cancarini; Enrico Imbasciati; Fabio Malberti
Journal:  J Nephrol       Date:  2005 Mar-Apr       Impact factor: 3.902

4.  Comparison of transposed brachiobasilic fistulas to upper arm grafts and brachiocephalic fistulas.

Authors:  M J Oliver; R L McCann; O S Indridason; D W Butterly; S J Schwab
Journal:  Kidney Int       Date:  2001-10       Impact factor: 10.612

Review 5.  Balancing Fistula First with Catheters Last.

Authors:  Eduardo Lacson; J Michael Lazarus; Jonathan Himmelfarb; T Alp Ikizler; Raymond M Hakim
Journal:  Am J Kidney Dis       Date:  2007-09       Impact factor: 8.860

6.  Considerations in the statistical analysis of hemodialysis patient survival.

Authors:  Christos Argyropoulos; Chung-Chou H Chang; Laura Plantinga; Nancy Fink; Neil Powe; Mark Unruh
Journal:  J Am Soc Nephrol       Date:  2009-07-30       Impact factor: 10.121

7.  Resolved: Fistulas are preferred to grafts as initial vascular access for dialysis. Pro.

Authors:  Anatole Besarab
Journal:  J Am Soc Nephrol       Date:  2008-05-28       Impact factor: 10.121

Review 8.  Clinical epidemiology of arteriovenous fistula in 2007.

Authors:  Pietro Ravani; Lawrence M Spergel; Arif Asif; Prabir Roy-Chaudhury; Anatole Besarab
Journal:  J Nephrol       Date:  2007 Mar-Apr       Impact factor: 3.902

Review 9.  Biology of arteriovenous fistula failure.

Authors:  Prabir Roy-Chaudhury; Lawrence M Spergel; Anatole Besarab; Arif Asif; Pietro Ravani
Journal:  J Nephrol       Date:  2007 Mar-Apr       Impact factor: 3.902

10.  Cardiovascular comorbidity and late referral impact arteriovenous fistula survival: a prospective multicenter study.

Authors:  Pietro Ravani; Giuliano Brunori; Salvatore Mandolfo; Giovanni Cancarini; Enrico Imbasciati; Daniele Marcelli; Fabio Malberti
Journal:  J Am Soc Nephrol       Date:  2004-01       Impact factor: 10.121

  10 in total
  6 in total

Review 1.  Optimizing renal replacement therapy in older adults: a framework for making individualized decisions.

Authors:  Manjula Kurella Tamura; Jane C Tan; Ann M O'Hare
Journal:  Kidney Int       Date:  2011-11-16       Impact factor: 10.612

Review 2.  Complications of the Arteriovenous Fistula: A Systematic Review.

Authors:  Ahmed A Al-Jaishi; Aiden R Liu; Charmaine E Lok; Joyce C Zhang; Louise M Moist
Journal:  J Am Soc Nephrol       Date:  2016-12-28       Impact factor: 10.121

3.  Temporal risk profile for infectious and noninfectious complications of hemodialysis access.

Authors:  Pietro Ravani; Brenda W Gillespie; Robert Ross Quinn; Jennifer MacRae; Braden Manns; David Mendelssohn; Marcello Tonelli; Brenda Hemmelgarn; Matthew James; Neesh Pannu; Bruce M Robinson; Xin Zhang; Ronald Pisoni
Journal:  J Am Soc Nephrol       Date:  2013-07-11       Impact factor: 10.121

4.  MicroRNA and Transcription Factor Gene Regulatory Network Analysis Reveals Key Regulatory Elements Associated with Prostate Cancer Progression.

Authors:  Mehdi Sadeghi; Bijan Ranjbar; Mohamad Reza Ganjalikhany; Faiz M Khan; Ulf Schmitz; Olaf Wolkenhauer; Shailendra K Gupta
Journal:  PLoS One       Date:  2016-12-22       Impact factor: 3.240

5.  Application of Parametric Models to a Survival Analysis of Hemodialysis Patients.

Authors:  Maryam Montaseri; Jamshid Yazdani Charati; Fateme Espahbodi
Journal:  Nephrourol Mon       Date:  2016-09-13

6.  Five long non-coding RNAs establish a prognostic nomogram and construct a competing endogenous RNA network in the progression of non-small cell lung cancer.

Authors:  Yong Yu; Kaiming Ren
Journal:  BMC Cancer       Date:  2021-04-23       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.